ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Tumor-Activated Prodrug (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. ImmunoGen was founded in 1981 and became a public company in 1989.